Pharmaceuticals, Biotechnology & Life Sciences

Pfizer’s latest Form 4 filings reveal phantom‑stock grants to non‑employee directors, boosting incentive alignment without diluting shares or affecting capital structure.

Explore how Novo Nordisk’s AI partnership, coramitug breakthrough, and buy‑back plan could reshape its growth, diversify its pipeline, and impact investors.

FDA approves weekly self‑injection of Saphnelo (anifrolumab) for SLE, offering the same proven safety and efficacy of the IV drug with greater convenience for patients.

Novartis eyes 5‑6% revenue growth and a €700‑€900 million NPV for Rhapsido, its first oral CSU therapy, amid strong oncology profits and strategic M&A prospects.

Japanese equity gains spotlight tech and robotics, revealing how healthcare can adopt AI and automation for cost‑efficient, high‑quality care.

Discover how Astellas Pharma’s 2023 earnings surge, 11 % revenue growth and R&D focus signal strong future momentum despite market dips.

Discover how Daiichi Sankyo’s latest earnings forecast signals rising profits, expanding revenue, and strong pharma growth ahead of its April 2026 financial release.

Discover how Sartorius Stedim Biotech’s Q4 2026 results reveal steady EPS growth, 14 % revenue lift, and a digital‑sustainability edge in a tight bioprocessing market.

Unilever’s pivot to wellness‑centric consumer health, backed by science‑based nutraceuticals, boosts margins and meets rising health‑conscious demand.

Regeneron’s next‑generation biologics strategy blends advanced protein engineering, AI‑driven discovery, and scalable manufacturing—fueling growth in oncology, immunology, and its core eye‑care hits.